What developmental therapies are most effective for speech delays in Myhre syndrome?

Speech‑language therapy that incorporates visual‑verbal cues, augmentative communication devices, and repetitive phoneme practice can accelerate speech milestones. Early intervention (starting before age 2) and consistent home practice are key. Therapists may also use play‑based techniques to encourage expressive language and social interaction, which can help mitigate autism‑like symptoms.

How can joint stiffness be managed to improve daily function in Myhre syndrome?

Physical therapy focused on gentle range‑of‑motion and stretching exercises is essential. A therapist can design a home program that includes passive and active movements, heat packs, and gentle resistance training. Splinting or orthotic devices may help maintain joint alignment. Consistent, short sessions (10–15 minutes) several times a day often yield better compliance and results than longer, infrequent visits.

When should a cardiology evaluation be scheduled for a child with Myhre syndrome, and what tests are indicated?

Because cardiac fibrosis can develop early, a baseline echocardiogram and ECG should be performed by age 2 or sooner if symptoms such as shortness of breath, fatigue, or palpitations appear. Follow‑up studies are recommended every 1–2 years, or more frequently if abnormalities are found. Early detection of valve thickening or arrhythmias allows timely medical or surgical intervention.

What early signs should prompt a hearing evaluation in a child with Myhre syndrome?

Hearing loss in Myhre syndrome often starts in early childhood and can worsen over time. Parents should watch for delayed speech, difficulty following simple commands, or frequent requests to repeat themselves. A pediatric audiologist should perform a baseline audiogram by age 2, and repeat testing every 12–18 months or sooner if symptoms change. Early identification allows timely hearing aids or cochlear implants, which can improve language development and reduce behavioral issues.

Myhre syndrome

Myhre syndrome is a rare autosomal‑dominant disorder caused by SMAD4 mutations, producing short stature, distinctive facial and skeletal features, and multi‑system fibrosis that can affect the heart, lungs, skin, and other organs.

Overview

Myhre syndrome is a rare condition that affects connective tissue, which provides strength and flexibility to structures throughout the body. The disorder presents a variety of signs and symptoms that can differ in severity, and some features become more apparent with age.

Clinical Features

Growth and Skeletal Abnormalities

Reduced growth beginning before birth and continuing through adolescence; low birth weight and short stature (shorter than about 97 % of peers).
Shortened long bones of the arms and legs, unusually short fingers and toes, and curved pinky fingers.
Thickening of the skull bones, flattened vertebral bodies (platyspondyly), broad ribs, and hypoplastic iliac wings.
Joint problems (arthropathy) with stiffness and limited mobility.

Facial Features

Narrow eyelid openings, deeply set eyes, short philtrum.
Underdeveloped upper jaw, protruding lower jaw (prognathism).
Possible cleft palate, cleft lip, or both.
Common ocular findings: strabismus, myopia, hyperopia, astigmatism, cataracts, and rarely pseudopapilledema.

Developmental, Neurocognitive, and Behavioral Features

Delayed development noticeable by age 5, with speech and language delay being most significant.
Motor milestones (crawling, walking) may be delayed but are eventually achieved.
Intellectual disability ranging from mild to moderate; some individuals attain employment or higher education.
Features resembling autism spectrum disorder, affecting communication and social interaction; severity varies and often improves over time.

Hearing

Hearing loss occurs in most individuals, usually beginning in childhood and gradually worsening, potentially contributing to learning and behavioral problems if not detected promptly.

Skin and Fibrosis

Stiff, thickened skin typically appearing in childhood on palms, soles, elbows, and knees, later spreading to other areas.
Fewer facial creases than age‑matched peers.
Scars may become unusually thickened (keloids or hypertrophic scars) after healing.

Cardiovascular System

Congenital heart defects present at birth.
Fibrosis of the heart and blood vessels leading to hypertension, valve or vessel stenosis.
Pericarditis (inflammation of the pericardium) and, rarely, restrictive cardiomyopathy.
These cardiovascular problems can be life‑threatening.

Respiratory System

Laryngotracheal stenosis and bronchial narrowing.
Restrictive pulmonary disease (difficulty filling the lungs).
Interstitial lung disease (widespread lung damage).
Respiratory complications can be life‑threatening.

Gastrointestinal Tract and Cancer Risk

Narrowing of the lower pylorus (pyloric stenosis) or upper duodenum (duodenal strictures) and severe constipation.
Increased risk of developing tumors, including endometrial cancer.

Genetics

Causes

Mutations in the SMAD4 gene cause Myhre syndrome. The SMAD4 protein transmits signals from the cell surface to the nucleus via the transforming growth factor‑beta (TGF‑β) pathway, influencing the activity of genes that regulate development of many body systems.

Studies suggest that the SMAD4 mutations produce an abnormally stable protein that remains active longer than normal, leading to altered TGF‑β signaling and the multisystem features of Myhre syndrome.

Inheritance

Myhre syndrome follows an autosomal dominant inheritance pattern—one altered copy of the SMAD4 gene is sufficient to cause the disorder.

In almost all cases the condition results from a de novo mutation in individuals with no family history; rarely, an affected person inherits the mutation from an affected parent.

Frequency

Myhre syndrome is a rare disorder; its prevalence is unknown. Almost 100 cases have been documented in the medical literature.

Other Names

LAPS syndrome
Laryngotracheal stenosis, arthropathy, prognathism, and short stature

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Myhre syndrome

Genetic and Rare Diseases Information Center

Myhre syndrome

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

MYHRE SYNDROME; MYHRS

Scientific Articles on PubMed

PubMed

References

Caputo V, Bocchinfuso G, Castori M, Traversa A, Pizzuti A, Stella L, Grammatico P, Tartaglia M. Novel SMAD4 mutation causing Myhre syndrome. Am J Med Genet A. 2014 Jul;164A(7):1835-40. doi: 10.1002/ajmg.a.36544. Epub 2014 Apr 8.
Caputo V, Cianetti L, Niceta M, Carta C, Ciolfi A, Bocchinfuso G, Carrani E, Dentici ML, Biamino E, Belligni E, Garavelli L, Boccone L, Melis D, Andria G, Gelb BD, Stella L, Silengo M, Dallapiccola B, Tartaglia M. A restricted spectrum of mutations in the SMAD4 tumor‑suppressor gene underlies Myhre syndrome. Am J Hum Genet. 2012 Jan 13;90(1):161-9. doi: 10.1016/j.ajhg.2011.12.011.
Garavelli L, Maini I, Baccilieri F, Ivanovski I, Pollazzon M, Rosato S, Iughetti L, Unger S, Superti‑Furga A, Tartaglia M. Natural history and life‑threatening complications in Myhre syndrome and review of the literature. Eur J Pediatr. 2016 Oct;175(10):1307-15. doi: 10.1007/s00431-016-2761-3. Epub 2016 Aug 25.
Le Goff C, Mahaut C, Abhyankar A, Le Goff W, Serre V, Afenjar A, Destree A, di Rocco M, Heron D, Jacquemont S, Marlin S, Simon M, Tolmie J, Verloes A, Casanova JL, Munnich A, Cormier‑Daire V. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet. 2011 Dec 11;44(1):85-8. doi: 10.1038/ng.1016.
Le Goff C, Michot C, Cormier‑Daire V. Myhre syndrome. Clin Genet. 2014 Jun;85(6):503-13. doi: 10.1111/cge.12365. Epub 2014 Apr 2.
Lin AE, Alali A, Starr LJ, Shah N, Beavis A, Pereira EM, Lindsay ME, Klugman S. Gain‑of‑function pathogenic variants in SMAD4 are associated with neoplasia in Myhre syndrome. Am J Med Genet A. 2020 Feb;182(2):328-337. doi: 10.1002/ajmg.a.61430. Epub 2019 Dec 14.
Lin AE, Brunetti‑Pierri N, Lindsay ME, Schimmenti LA, Starr LJ. Myhre Syndrome. 2017 Apr 13 [updated 2024 Dec 12]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993‑2026.
Lin AE, Michot C, Cormier‑Daire V, L'Ecuyer TJ, Matherne GP, Barnes BH, Humberson JB, Edmondson AC, Zackai E, O'Connor MJ, Kaplan JD, Ebeid MR, Krier J, Krieg E, Ghoshhajra B, Lindsay ME. Gain‑of‑function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. Am J Med Genet A. 2016 Oct;170(10):2617-31. doi: 10.1002/ajmg.a.37739.
Lindor NM, Gunawardena SR, Thibodeau SN. Mutations of SMAD4 account for both LAPS and Myhre syndromes. Am J Med Genet A. 2012 Jun;158A(6):1520-1. doi: 10.1002/ajmg.a.35374. Epub 2012 May 14.
McGowan R, Gulati R, McHenry P, Cooke A, Butler S, Keng WT, Murday V, Whiteford M, Dikkers FG, Sikkema‑Raddatz B, van Essen T, Tolmie J. Clinical features and respiratory complications in Myhre syndrome. Eur J Med Genet. 2011 Nov‑Dec;54(6):e553-9. doi: 10.1016/j.ejmg.2011.07.001. Epub 2011 Jul 21.
Meerschaut I, Beyens A, Steyaert W, De Rycke R, Bonte K, De Backer T, Janssens S, Panzer J, Plasschaert F, De Wolf D, Callewaert B. Myhre syndrome: A first familial recurrence and broadening of the phenotypic spectrum. Am J Med Genet A. 2019 Dec;179(12):2494-2499. doi: 10.1002/ajmg.a.61377. Epub 2019 Oct 9.
Michot C, Le Goff C, Mahaut C, Afenjar A, Brooks AS, Campeau PM, Destree A, Di Rocco M, Donnai D, Hennekam R, Heron D, Jacquemont S, Kannu P, Lin AE, Manouvrier‑Hanu S, Mansour S, Marlin S, McGowan R, Murphy H, Raas‑Rothschild A, Rio M, Simon M, Stolte‑Dijkstra I, Stone JR, Sznajer Y, Tolmie J, Touraine R, van den Ende J, Van der Aa N, van Essen T, Verloes A, Munnich A, Cormier‑Daire V. Myhre and LAPS syndromes: clinical and molecular review of 32 patients. Eur J Hum Genet. 2014 Nov;22(11):1272-7. doi: 10.1038/ejhg.2013.288. Epub 2014 Jan 15.
Starr LJ, Grange DK, Delaney JW, Yetman AT, Hammel JM, Sanmann JN, Perry DA, Schaefer GB, Olney AH. Myhre syndrome: Clinical features and restrictive cardiopulmonary complications. Am J Med Genet A. 2015 Dec;167A(12):2893-901. doi: 10.1002/ajmg.a.37273. Epub 2015 Sep 30.